Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Broad, Gyros, and More

Premium

Louis Gerstner has been elected chairman of the Broad Institute's board of directors, succeeding outgoing chair Diana Chapman Walsh, who will continue to serve on the board as vice chair.

Gerstner was elected to the Broad's board in 2010. He was CEO and chairman of the board of IBM from 1993 to 2002 and has also served as chairman of the Carlyle Group and CEO of RJR Nabisco.


Gyros said this week that it has appointed Henrik Bjorkman chief technology officer and vice president of technical affairs.

Previously, Bjorkman was director of MicroCal R&D at GE Healthcare Life Sciences.


Enzo Biochem's shareholders have re-elected Gregory Bortz and Dov Perlysky to serve on the company's board of directors for three-year terms.

Bortz is founder and managing partner of Creo Capital Partners and he previously was senior VP of the investment banking division of Lehman Brothers. Perlysky has been a managing member of the private investment firm Nesher and a director of the mutual fund Engex, and he has served on the board of directors at Pharma-Bio Serv and Highlands Bancorp.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.